tbuckley/cabot-search huggingface dataset:
Obama calls on Congress to fully fund Zika response
Authors: Michael McCarthy
Journal: BMJ (2016)

After a White House briefing with his administration’s top health experts on 20 May, US president Barack Obama renewed his call for Congress to fully fund his request for $1.9 billion (£1.31b; €1.7b) in emergency funding to combat the spread of the Zika virus in the US and abroad. Obama made his first request for the funds in February.1

Earlier in the week the Senate, in a compromise between Democrats and Republicans, voted to appropriate about half the president’s request, $1.1b. The House of Representatives, however, voted to provide far less, just $622m or about a third of what the White House said was needed.

Over the past several months, the administration has shifted funds from other programs to support the government’s response, but the president said that full funding …
Abstract IA23: Ovarian cancer screening.
Authors: Usha Menon
Journal: Clinical Cancer Research (2016)

Abstract Ovarian cancer is the 5th most common cause of cancer death among women in the UK, with ten-year survival rates of 35%. The continued high case fatality ratio has underpinned efforts to develop a screening strategy that could impact on mortality. In the UK large ovarian cancer screening trials have been completed both in the general (United Kingdom Collaborative Trial of Ovarian Cancer Screening - UKCTOCS) and high-risk (UK Familial Ovarian Cancer Screening Study UKFOCSS) population. Emerging evidence from UKCTOCS is encouraging with the multimodal strategy appearing to have detected double the number of invasive epithelial ovarian/fallopian tube cancer during incidence screening compared to a fixed cut-off for serum CA125 used previously. The key issue is impact on ovarian cancer mortality, which will be available from UKCTOCS in December 2015. Meanwhile new insights into carcinogenesis with a better understanding of the target lesion, improved design of biomarker discovery studies, a focus on detecting low volume disease using cancer specific markers, novel biospecimens such as endocervical samples, targeted imaging and time series algorithms for interpreting marker profile suggests that a new era in ovarian cancer screening is underway. Citation Format: Usha Menon. Ovarian cancer screening. [abstract]. In: Proceedings of the AACR Special Conference on Advances in Ovarian Cancer Research: Exploiting Vulnerabilities; Oct 17-20, 2015; Orlando, FL. Philadelphia (PA): AACR; Clin Cancer Res 2016;22(2 Suppl):Abstract nr IA23.
Abstract P4-02-14: Incidentally detected enhancing lesions found on preoperative breast MRI: Analysis of T2 signal intensity and apparent diffusion coefficient significantly improve classification
Authors: O Arponen, M Sudah, A Masarwah, A Sutela, R Vanninen
Journal: Cancer Research (2016)

Abstract Purpose and Background− Reportedly, magnetic resonance imaging (MRI) detects mammographically and sonographically (US) occult incidental lesions in 10-29% of patients with a malignant primary breast lesion. We evaluated diagnostic performance of the BI-RADS reporting system and utility of T2- and diffusion weighted imaging (DWI) for MRI detected additional lesions. Methods− This prospective study protocol included 3.0T structural breast MRI with T2-weighted imaging and DWI performed according to EUSOMA guidelines in 112 consecutive patients with primary breast lesions (mean age 57.0±12.7 years, range 38-80 years). Breast lesions with one or more suspective feature according to the BI-RADS lexigon were biopsied. T2 signal intensity (SI) and DWI findings were assessed. Results− Altogether 33 (29.5%) patients had 36 primarily MRI detected incidental additional lesions. In addition, 36 sographically or mammographically detected lesions were histopathologically confirmed and a total of 8 lesions were followed up. Of incidental lesions, 16 (44.4%) proved to be malignant. Mean size was 0.82±0.29 cm (range 0.5 cm to 1.5 cm) and 1.5±1.61 cm (range 0.5 cm to 5.0 cm) for 29 mass lesions and 7 NMLE lesions, respectively. In mass lesions, traditional morphological or kinetic features were not correlated to malignancy except for fast initial enhancement (P=0.003). The BI-RADS classification produced 100% sensitivity, 40% specificity, 53.3% PPV, 100% NPV and 51.7% overall accuracy. Both the low T2 SI (P=0.05) and low ADC values (P&amp;lt;0.001) significantly correlated with malignancy yeilding improved 86.7%/90.5% specificity and 65.0%/90.5% negative predictive value, respectively (McNemar's test, P&amp;lt;0.01). Combining low T2 SI, ADC values or morphologic or kinetic features did not improve the results. Conclusion− A single suspective morphologic or kinetic MRI feature is the most sensitive parameter to discover an incidental breast malignancy, as some incidental lesions present with only a few suspicious MRI feature. Specificity of MRI is improved when T2 SI or DWI are addressed. Citation Format: Arponen O, Sudah M, Masarwah A, Sutela A, Vanninen R. Incidentally detected enhancing lesions found on preoperative breast MRI: Analysis of T2 signal intensity and apparent diffusion coefficient significantly improve classification. [abstract]. In: Proceedings of the Thirty-Eighth Annual CTRC-AACR San Antonio Breast Cancer Symposium: 2015 Dec 8-12; San Antonio, TX. Philadelphia (PA): AACR; Cancer Res 2016;76(4 Suppl):Abstract nr P4-02-14.
Prognostic Value of Myocardial Perfusion Tomographic Imaging in Patients After Percutaneous Transluminal Coronary Angioplasty
Authors: MILAN KAMÍNEK, MIROSLAV MYSLIVE˘CEK, MARCELA ŠKVA˘RILOVÁ, VÁCLAV HUŠÁK, PAVEL KORANDA, OTTO LANG
Journal: Clinical Nuclear Medicine (2000)

Purpose The authors assessed the prognostic value of stress myocardial perfusion tomographic imaging (SPECT) in patients with recurrent angina or inconclusive results of exercise electrocardiographic tests after successful percutaneous transluminal coronary angioplasty (PTCA). Materials and Methods After PTCA, 70 patients (54 men, 16 women; 41 after myocardial infarction; mean age, 56 ± 9 years) underwent Tl-201 or Tc-99m sestamibi SPECT studies. SPECT patterns were divided into normal (n = 25), fixed defects (n = 15), and reversible or combined fixed plus reversible defects (n = 30). A cardiac event was defined as either cardiac death, nonfatal myocardial infarction, or unstable angina requiring further revascularization. Results During an average follow-up of 25 ± 10 months, two patients had severe outcomes (one cardiac death and one nonfatal myocardial infarction), and revascularization was required in 13 patients. In patients with normal SPECT or fixed defects, the annual event rate was low (1.2%), with only one revascularization. In patients with reversible or combined defects, the annual event rate was significantly greater (22.4%; chi square = 17.32, P = 0.00003). Conclusions Normal perfusion or fixed defects predict a benign prognosis in patients after successful PTCA. The presence of stress-induced reversible defects appears to be the best predictor of future cardiac events.
Mammography For Breast Cancer
Authors: A J Present
Journal: CA A Cancer Journal for Clinicians (1965)

Ad Hoc Committee on Mam mogi-aphy of the AmericanCollege of Radiology ivh/ch ha.s been studying the applicability of this procedure to bi-east cancer, I want to ask you if this technique is here to stay now after the many years that docto,-.s-havebeen ti-ying to use X i-
Cessation of long-acting β2-agonist in children with persistent asthma on inhaled corticosteroids
Authors: Francine M. Ducharme, Roxanne Gagnon, Brigitte Bénard, Sze Man Tse, Robert Thivierge
Journal: European Respiratory Journal (2016)

International guidelines recommend adding long-acting β2-agonists (LABA) to inhaled corticosteroids (ICS) as a step 3 or 4 strategy in children in whom ICS, with or without adjunct therapy, is ineffective in adequately controlling asthma [1–4]. Contrary to adults, the beneficial effects of ICS/LABA in children are limited to improving lung function and short-acting β2-agonist use (SABA), with no significant reduction in symptoms compared with ICS alone [5]; moreover, a nonsignificant trend towards more exacerbations requiring oral corticosteroids and/or hospital admissions raised concerns [5]. Asthma-related intubations and deaths linked to LABA [6] have led the US Food and Drug Administration to issue label changes recommending that LABA is discontinued once asthma control has been achieved [7]. Most asthmatic children can be successfully weaned off long-acting β2-agonists to inhaled corticosteroid monotherapy <http://ow.ly/10oTtI> We are indebted to Pierre Gaudreault (University of Montreal, Montreal, Canada) and Caroline Chartrand (CHU Sainte-Justine, Montreal, Canada) who assisted in the diligent data collection during their patients' medical visits and thank the parents of the children enrolled in this study.
The Use of Granulocyte Colony-Stimulating Factor During Retroviral Transduction on Fibronectin Fragment CH-296 Enhances Gene Transfer Into Hematopoietic Repopulating Cells in Dogs
Authors: Martin Goerner, Benedetto Bruno, Peter A. McSweeney, Greg Buron, Rainer Storb, Hans-Peter Kiem
Journal: Blood (1999)
The Cytological Effect of Chemicals on Ascites Sarcomas. I. Partial Damage in Tumor Cells by Podophyllin, Followed by Temporary Regression and Prolongation of Life of Tumor-Bearing Rats&lt;xref ref-type="fn" rid="fn1"&gt;&lt;sup&gt;2&lt;/sup&gt;&lt;/xref&gt;
Authors: S MAKINO, T TANAKA
Journal: JNCI Journal of the National Cancer Institute (1953)
Update On The Safety and Efficacy Of The Pan Class I PI3K Inhibitor SAR245408 (XL147) In Chronic Lymphocytic Leukemia and Non-Hodgkin’s Lymphoma Patients
Authors: Jennifer R. Brown, Matthew S. Davids, Jordi Rodon, Pau Abrisqueta, Coumaran Egile, Rodrigo Ruiz-Soto, Farrukh Awan
Journal: Blood (2013)
Translocation t(9;11)(p21;q23) with acute myelomonocytic leukemia after chemotherapy for osteosarcoma: good response to antileukemic drugs.
Authors: P Fenaux, J P Jouet, F Bauters, J L Lai, P Lepelley
Journal: Journal of Clinical Oncology (1987)

Article Tools Article Tools OPTIONS & TOOLS Export Citation Track Citation Add To Favorites Rights & Permissions COMPANION ARTICLES No companion articles ARTICLE CITATION DOI: 10.1200/JCO.1987.5.8.1304 Journal of Clinical Oncology - published online before print September 22, 2016 PMID: 2442320 Translocation t(9;11)(p21;q23) with acute myelomonocytic leukemia after chemotherapy for osteosarcoma: good response to antileukemic drugs. P FenauxxP FenauxSearch for articles by this author , J P JouetxJ P JouetSearch for articles by this author , F BautersxF BautersSearch for articles by this author , J L LaixJ L LaiSearch for articles by this author , P LepelleyxP LepelleySearch for articles by this author https://doi.org/10.1200/JCO.1987.5.8.1304 PDF "Translocation t(9;11)(p21;q23) with acute myelomonocytic leukemia after chemotherapy for osteosarcoma: good response to antileukemic drugs.." Journal of Clinical Oncology, 5(8), pp. 1304–1305© 1987 by American Society of Clinical Oncology
Stable Standard Preparations of the Rous Sarcoma Virus Preserved by Freezing and Storage at Low Temperatures
Authors: W. Ray Bryan, John B. Moloney, Dorothy Calnan
Journal: JNCI Journal of the National Cancer Institute (1954)

Stable Standard Preparations of the Rous Sarcoma Virus Preserved by Freezing and Storage at Low Temperatures W. Ray Bryan, W. Ray Bryan National Cancer Institute,3Bethesda, Md. Search for other works by this author on: Oxford Academic PubMed Google Scholar John B. Moloney, John B. Moloney National Cancer Institute,3Bethesda, Md. Search for other works by this author on: Oxford Academic PubMed Google Scholar Dorothy Calnan Dorothy Calnan National Cancer Institute,3Bethesda, Md. Search for other works by this author on: Oxford Academic PubMed Google Scholar JNCI: Journal of the National Cancer Institute, Volume 15, Issue 2, October 1954, Pages 315–329, https://doi.org/10.1093/jnci/15.2.315 Published: 01 October 1954 Article history Received: 14 June 1954 Published: 01 October 1954
Abstract B14: Hematopoietic RIPK1 deficiency results in bone marrow failure due to apoptosis and RIPK3-mediated necroptosis.
Authors: Justine R. Roderick, Nicole C. Hermance, Matija Zelic, Apostolos Polykratis, Manolis Pasparakis, Michelle A. Kelliher
Journal: Clinical Cancer Research (2015)

Abstract The serine/threonine kinase RIPK1 is recruited to the TNF receptor 1 to mediate pro-inflammatory signaling and to regulate TNF-induced apoptosis and necroptosis. The kinase activity of RIPK1 is required for RIPK3 activation and induction of necroptosis, an inflammatory form of cell death. Although Ripk3-/- mice are viable, a RIPK1 deficiency results in postnatal lethality. To identify the lineages and cell types that depend on RIPK1 for survival, we generated conditional Ripk1 mice. Tamoxifen administration to adult RosaCreERT2Ripk1fl/fl mice results in lethality due to cell death in the intestinal and hematopoietic lineages. Similarly, Ripk1 deletion in cells of the hematopoietic lineage stimulates pro-inflammatory cytokine and chemokine production and hematopoietic cell death, resulting in bone marrow failure. The cell death reflects cell intrinsic survival roles for RIPK1 in hematopoietic stem and progenitor cells, as Vav-iCre Ripk1fl/fl fetal liver cells failed to reconstitute hematopoiesis in lethally irradiated recipients. We demonstrate that a RIPK3 deficiency partially rescues hematopoiesis in Vav-iCre Ripk1fl/fl mice, revealing that RIPK1 mediates survival by preventing RIPK3-mediated necroptosis. However, Vav-iCre Ripk1fl/fl Ripk3-/- progenitors remain TNF sensitive in vitro and fail to repopulate irradiated mice. These genetic studies reveal that a hematopoietic RIPK1 deficiency triggers both apoptotic and necroptotic death that is partially prevented by a RIPK3 deficiency. Thus, in contrast to in vitro studies, RIPK1 functions in hematopoietic cells to negatively regulate RIPK3 and prevent inflammation. Citation Format: Justine R. Roderick, Nicole C. Hermance, Matija Zelic, Apostolos Polykratis, Manolis Pasparakis, Michelle A. Kelliher. Hematopoietic RIPK1 deficiency results in bone marrow failure due to apoptosis and RIPK3-mediated necroptosis. [abstract]. In: Proceedings of the AACR Special Conference on Hematologic Malignancies: Translating Discoveries to Novel Therapies; Sep 20-23, 2014; Philadelphia, PA. Philadelphia (PA): AACR; Clin Cancer Res 2015;21(17 Suppl):Abstract nr B14.
Abstract B13: Discovery of novel subtype-specific ovarian cancer biomarkers via integrated tissue proteomics.
Authors: Felix Leung, Marcus Q. Bernardini, Blaise Clarke, Marjan Rouzbahman, Eleftherios P. Diamandis, Vathany Kulasingam
Journal: Clinical Cancer Research (2016)

Abstract Introduction and Objectives: It is evident that ovarian cancer (OvCa) is not a single disease but is made up of several distinct subtypes, including serous, endometrioid, clear cell and mucinous. The gold-standard biomarker CA125 performs well in serous but not in the other histotypes. We hypothesize that a more focused discovery effort (on non-serous OvCa biomarkers and/or markers that can complement serum CA125) may bring about a sensitivity that is acceptable for all histotypes and be suitable for early diagnosis of OvCa. Methods: Tissues from patients diagnosed with endometrioid (EC), clear cell (CC), and mucinous ovarian carcinoma (MC), as well as from their appropriate controls (endometriosis and healthy endometrium for EC and CC; mucinous cystadenoma for MC) were subjected to proteomic analysis using a label-free, offline 2-dimensional liquid chromatography tandem mass spectrometry-based approach. Discovery candidates were then filtered using an in-house developed algorithm combining publicly-available resources with our own warehouse of transcriptomic and proteomic sets. Results and Discussion: Over 8000 unique proteins were identified in this proteomic exercise; specifically, approximately 1500 protein unique to MC, 1100 unique to CC, and 3000 unique to EC were identified when comparing the appropriate cases and controls. A curated list of 60 high-potential candidates was generated after using a range of bioinformatics tools to ensure criteria based on factors including (but not limited to) tissue specificity, cellular localization and transcriptional upregulation were met. These 60 candidates represent putative subtype-specific markers which will be further analyzed and validated in serum cohorts. Conclusions: The identification and validation of markers specific to the non-serous subtypes of OvCa remains an unmet clinical need. With our list of putative subtype-specific markers, we aim to develop a novel biomarker panel able to detect all OvCa histotypes with greater sensitivity and specificity than any existing clinical tools. Citation Format: Felix Leung, Marcus Q. Bernardini, Blaise Clarke, Marjan Rouzbahman, Eleftherios P. Diamandis, Vathany Kulasingam. Discovery of novel subtype-specific ovarian cancer biomarkers via integrated tissue proteomics. [abstract]. In: Proceedings of the AACR Special Conference on Advances in Ovarian Cancer Research: Exploiting Vulnerabilities; Oct 17-20, 2015; Orlando, FL. Philadelphia (PA): AACR; Clin Cancer Res 2016;22(2 Suppl):Abstract nr B13.
CXCR2 and CXCL4 regulate survival and self-renewal of hematopoietic stem/progenitor cells
Authors: Amy Sinclair, Laura Park, Mansi Shah, Mark Drotar, Simon Calaminus, Lisa E. M. Hopcroft, Ross Kinstrie, Amelie V. Guitart, Karen Dunn, Sheela A. Abraham, Owen Sansom, Alison M. Michie, Laura Machesky, Kamil R. Kranc, Gerard J. Graham, Francesca Pellicano, Tessa L. Holyoake
Journal: Blood (2016)
Stat Bite: Trends in U.S. Cancer Mortality by Age Group, 1973-1989
Authors: B. F. Hankey
Journal: JNCI Journal of the National Cancer Institute (1992)

Journal Article Stat Bite : Trends in U.S. Cancer Mortality by Age Group, 1973–1989 Get access Benjamin F. Hankey, Sc.D. Benjamin F. Hankey, Sc.D. Search for other works by this author on: Oxford Academic PubMed Google Scholar JNCI: Journal of the National Cancer Institute, Volume 84, Issue 18, 16 September 1992, Page 1391, https://doi.org/10.1093/jnci/84.18.1391 Published: 16 September 1992
Case 79-1963
Authors: Howard Ulfelder, Robert E. Scully
Journal: New England Journal of Medicine (1963)

Presentation of CaseAn eighty-three-year-old woman entered the hospital because of abdominal pain.The patient had been in good health until six weeks previously, when dull, aching pain developed in both lower quadrants of the abdomen, accompanied by an increase in severity of lifelong constipation, with only the occasional passage of a small, watery stool. Dysuria and nocturia occurred, but there was no urinary frequency or urgency, weight loss, anorexia, fever, chills or rectal bleeding. Cholecystotomy had been performed in the remote past, and for several years she had taken tolbutamide because of diabetes mellitus. There was no vaginal bleeding . . .
Evolving Use of Androgen Deprivation Therapy in Prostate Cancer Management
Authors: James L. Mohler
Journal: Journal of the National Comprehensive Cancer Network (2016)

Since its introduction more than 70 years ago, the use of androgen deprivation therapy (ADT) for prostate cancer has evolved to become part of a multimodal management approach. In this presentation from the NCCN 21st Annual Conference, James L. Mohler, MD, reviewed data that inform these strategies and gave his bottom-line recommendations on issues such as ADT plus radiotherapy, continuous versus intermittent ADT, ADT for positive nodes, and ADT plus docetaxel. He suggested that ADT plus radiation therapy should be used in patients at high risk, intermittent ADT is more appropriate for most patients than continuous ADT, and docetaxel should be given with ADT for high-volume metastatic disease.
Abstract 1082: High-throughput,purification-free, multiplexed profiling of circulating miRNA for discovery,validation, and diagnostics
Authors: Jessica Tytell, Issac Stoner, Michael Tackett, Graeme Doran, Conor Rafferty, Andreas Windemuth, Daniel Pregibon
Journal: Cancer Research (2016)

Abstract To address the needs for circulating miRNA biomarker validation, we developed the Multiplexed Circulating microRNA assay. This assay enables the detection of up to 68 microRNA targets per sample in 96-well format with readout on standard flow cytometers and analysis with an included bioinformatics software package. The Circulating microRNA assay combines particle-based multiplexing, using patented Firefly hydrogel particles, with single-step RT-PCR signal amplification using universal primers. Thus, the Circulating microRNA assay leverages PCR sensitivity while eliminating the need for separate reverse transcription reactions and mitigating amplification biases introduced by target-specific qPCR. Furthermore, the ability to multiplex targets in each well eliminates the need to split valuable samples into multiple reactions. Results from the Circulating microRNA assay are displayed and interpreted using our included Firefly Analysis Workbench, which allows visualization, normalization, and export of experimental data with only a few mouse clicks. To aid discovery and validation of biomarkers, we have generated fixed panels for Oncology, Cardiology, Neurology, Immunology, and Liver Toxicology. These carefully curated panels include hemolysis markers to assess sample quality, as well as critical normalization factors. Here we present the data from several studies investigating circulating and tumor microRNA profiles using the Firefly Circulating microRNA Assay Fixed Panels. Together, this novel combination of bioinformatics tools and multiplexed, high-sensitivity assays enables rapid discovery and validation of microRNA biomarker signatures from fluid specimens. Citation Format: Jessica Tytell, Issac Stoner, Michael Tackett, Graeme Doran, Conor Rafferty, Andreas Windemuth, Daniel Pregibon. High-throughput,purification-free, multiplexed profiling of circulating miRNA for discovery,validation, and diagnostics. [abstract]. In: Proceedings of the 107th Annual Meeting of the American Association for Cancer Research; 2016 Apr 16-20; New Orleans, LA. Philadelphia (PA): AACR; Cancer Res 2016;76(14 Suppl):Abstract nr 1082.
AMA Members' Retirement Plan
Authors: A MONTAGU
Journal: JAMA (1966)

Our website uses cookies to enhance your experience. By continuing to use our site, or clicking "Continue," you are agreeing to our Cookie Policy | Continue JAMA HomeNew OnlineCurrent IssueFor Authors Publications JAMA JAMA Network Open JAMA Cardiology JAMA Dermatology JAMA Health Forum JAMA Internal Medicine JAMA Neurology JAMA Oncology JAMA Ophthalmology JAMA Otolaryngology–Head & Neck Surgery JAMA Pediatrics JAMA Psychiatry JAMA Surgery Archives of Neurology & Psychiatry (1919-1959) Podcasts Clinical Reviews Editors' Summary Medical News Author Interviews More JN Learning / CMESubscribeJobsInstitutions / LibrariansReprints & Permissions Terms of Use | Privacy Policy | Accessibility Statement 2023 American Medical Association. All Rights Reserved Search All JAMA JAMA Network Open JAMA Cardiology JAMA Dermatology JAMA Forum Archive JAMA Health Forum JAMA Internal Medicine JAMA Neurology JAMA Oncology JAMA Ophthalmology JAMA Otolaryngology–Head & Neck Surgery JAMA Pediatrics JAMA Psychiatry JAMA Surgery Archives of Neurology & Psychiatry Input Search Term Sign In Individual Sign In Sign inCreate an Account Access through your institution Sign In Purchase Options: Buy this article Rent this article Subscribe to the JAMA journal
Treosulfan-based conditioning for allogeneic HSCT in children with chronic granulomatous disease: a multicenter experience
Authors: Beatriz Morillo-Gutierrez, Rita Beier, Kanchan Rao, Lauri Burroughs, Ansgar Schulz, Anna-Maria Ewins, Brenda Gibson, Petr Sedlacek, Ladislav Krol, Brigitte Strahm, Irina Zaidman, Krzysztof Kalwak, Julie-An Talano, Ann Woolfrey, Chris Fraser, Isabelle Meyts, Ingo Müller, Jacek Wachowiak, Maria Ester Bernardo, Paul Veys, Karl-Walter Sykora, Andrew R. Gennery, Mary Slatter
Journal: Blood (2016)